Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis (PSC) is a cholestatic liver illness that is chronic and progressive and has no known cause. PSC is characterised by inflammation, fibrosis, and/or stricturing of the intra- and/or extrahepatic biliary ducts. PSC often develops over time and might result in cholestasis and liver failure as consequences. Without a liver transplant, the median period from diagnosis to death is about ten years.

“Primary Sclerosing Cholangitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.

The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Primary Sclerosing Cholangitis treatment therapies with a considerable amount of success over the years. Primary Sclerosing Cholangitis Key players such as – Qing Bile Therapeutics, BiomX, Albireo Pharma, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Gilead Sciences, and others, are developing therapies for the Primary Sclerosing Cholangitis treatment 

• Primary Sclerosing Cholangitis Emerging therapies such as – QBT-002, BX-003, A-3907, CS0159, CM 101, Volixibat, PLN-74809, Cilofexor, and others are expected to have a significant impact on the Primary Sclerosing Cholangitis market in the coming years.   
• Gilead sciences initiated a a Phase III, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of GS-9674 in subjects with primary sclerosing cholangitis (PSC) without cirrhosis

Route of Administration

Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment

• Primary Sclerosing Cholangitis Assessment by Product Type
• Primary Sclerosing Cholangitis By Stage and Product Type
• Primary Sclerosing Cholangitis Assessment by Route of Administration
• Primary Sclerosing Cholangitis By Stage and Route of Administration
• Primary Sclerosing Cholangitis Assessment by Molecule Type
• Primary Sclerosing Cholangitis by Stage and Molecule Type

DelveInsight’s Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Primary Sclerosing Cholangitis Therapeutics Market include:

Key companies developing therapies for Primary Sclerosing Cholangitis are – Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic, Mirum Pharmaceuticals, Chemomab Therapeutics, Cascade Pharmaceuticals, Qing Bile Therapeutics, Engitix, BiomX, COUR Pharmaceutical, Avolynt, Inc., Selecta Biosciences, Gannex Pharma, LISCure Bioscience, Genfit,  HighTide Therapeutics, Calliditas Therapeutics, Invea Therapeutics, and others

Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:

• QBT-002: Qing Bile Therapeutics
• BX-003: BiomX
• A-3907: Albireo Pharma
• CS0159: Cascade Pharmaceuticals
• CM 101: Chemomab Therapeutics
• Volixibat: Mirum Pharmaceuticals
• PLN-74809: Pliant Therapeutics
• Cilofexor: Gilead Sciences

Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline TherapeuticAssessment-

https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight

Primary Sclerosing Cholangitis Pipeline Analysis:

The Primary Sclerosing Cholangitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
• Primary Sclerosing Cholangitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies

Primary Sclerosing Cholangitis Pipeline Market Drivers

• Increasing prevalence of diseases associated with PSC such as liver cancer and inflammatory bowel disease
• Large number of pipeline molecules

Primary Sclerosing Cholangitis Pipeline Market Barriers

• Withdrawal of molecules from late clinical stages
• Lack of skilled professionals or trained expertise

Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight    

• Coverage: Global
• Key Primary Sclerosing Cholangitis Companies: Qing Bile Therapeutics, BiomX, Albireo Pharma, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Gilead Sciences, and others
• Key Primary Sclerosing Cholangitis Therapies: QBT-002, BX-003, A-3907, CS0159, CM 101, Volixibat, PLN-74809, Cilofexor, and others
• Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
• Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers 

Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting